Shree Ganesh Remedies shareholders overwhelmingly approved all four resolutions at its 31st Annual General Meeting on September 12, 2026. The company reported a 79.10% participation rate in the electronic voting process, with promoters casting votes on 100% of their outstanding shares.

The meeting, held via Video Conferencing or Other Audio-Visual Means, concluded at 11:58 am. Chairman and Managing Director Chandulal Manubhai Kothia chaired the session, while Whole-time Director and CFO Parth Chandulal Kothia presented the financial overview for FY26. Company Secretary Aditya Vikrambhai Patel submitted the voting results to BSE Limited pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results Overview

A total of 8,255 shareholders were on record as of September 5, 2026. Of these, 50 shareholders attended via video conferencing (7 promoters and 43 public shareholders). No shareholders were present in person or through proxy.

The voting was conducted electronically from September 9 to September 11, 2026, and during the AGM. CS Vishal Thawani of VTSN & Associates LLP served as the scrutinizer.

Key Resolutions Approved

Adoption of Financial Statements Shareholders approved the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. This ordinary resolution received support from 100% of promoter votes and 99.99% of public non-institutional votes. Only eight votes were cast against the resolution, all from remote e-voting by public non-institutional shareholders.

Director Reappointment The meeting approved the reappointment of Mr. Chandulal Manubhai Kothia (DIN: 00652806), who retires by rotation. The promoter group, holding 9,350,529 shares, voted unanimously in favor. Public institutional shareholders also voted 100% in favor.

Cost Auditor Remuneration Shareholders ratified the remuneration payable to M/s. M.I. Prajapati & Associates LLP for the financial year ending March 31, 2027. This resolution saw slightly lower participation from public non-institutional investors (20.36%) compared to the financial statement adoption (23.84%), though support remained near-universal at 99.99%.

Independent Director Appointment The special resolution to appoint Ms. Hiral Ankitkumar Shah (DIN: 07164025) as an independent director was passed with the requisite majority. Like the cost auditor resolution, it received 100% support from promoters and institutions.

Scrutinizer’s Report

The scrutinizer confirmed that the e-voting facility was provided by Central Depository Services (India) Limited (CDSL). Votes cast via remote e-voting were blocked for those members who also voted during the AGM via VC/OAVM, ensuring no double voting. The data was unblocked and downloaded in the presence of two independent witnesses after the conclusion of the meeting.

Shree Ganesh Remedies Limited reported a significant contraction in both top-line and bottom-line figures for the first quarter of FY26. The Ankleshwar-based specialty chemicals manufacturer posted a consolidated net profit after tax of ₹1.12 crore for the quarter ended June 30, 2026, down from ₹3.45 crore in the same period last year.

Revenue from operations declined by 41.8% year-on-year to ₹14.36 crore, compared to ₹24.67 crore in Q1FY25. This sequential drop follows a strong fourth quarter of FY25, where revenue stood at ₹33.20 crore. The company’s earnings per share (EPS) for the quarter were ₹0.87, a sharp decrease from ₹2.68 in Q1FY25.

Financial Performance

The decline in revenue was accompanied by a compression in operating margins. Standalone EBITDA for the quarter was ₹4.29 crore, representing an EBITDA margin of 28.05%. This is lower than the 31.42% margin recorded in Q1FY25 and the 36.23% margin seen in the preceding quarter (Q4FY25).

For the full fiscal year FY25, the company had reported total income of ₹109.29 crore and a net profit after tax of ₹17.76 crore.

What the Numbers Show

The divergence between the sequential and year-on-year performance highlights the volatility in the company’s recent operational cycle. While the current quarter shows a significant YoY decline, it also represents a steep drop from the peak performance recorded in Q4FY25, where revenue was more than double the current quarter’s figure. The compression in EBITDA margins suggests that cost structures did not adjust proportionally to the revenue decline, or that product mix shifted toward lower-margin offerings during the period.

Board Approval

The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors in a meeting held on August 12, 2026. The results have been filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.